+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Geographic Variation in the Quality and Cost of Care for Patients with Rheumatoid Arthritis



Geographic Variation in the Quality and Cost of Care for Patients with Rheumatoid Arthritis



Journal of Managed Care and Specialty Pharmacy 22(12): 1472-1481



There is considerable push to improve value in health care by simultaneously increasing quality while lowering or containing costs. However, for diseases that are best treated with comparatively expensive treatments, such as rheumatoid arthritis (RA), there could be tension between these aims. In this study, we measured geographic variation in quality, access, and cost for patients with RA, a disease with effective but costly specialty treatments. To assess the geographic differences in the quality, access, and cost of care for patients with RA. Using large claims databases covering the period between 2008 and 2014, we measured quality of care metrics by metropolitan statistical areas (MSAs) for patients with RA. Quality measures included use of disease-modifying antirheumatic drugs (DMARDs) and tuberculosis (TB) screening before initiating biologic DMARD therapy. Access to care measures included measured detection and the share of patients with RA who visited a rheumatologist. Regression models were used to control for differences in patient demographics and health status across MSAs. For the 501,376 patients diagnosed with RA, in the average MSA 64.1% of RA patients received a DMARD, and 29.6% of RA patients initiating a biologic DMARD appropriately received a TB screening. Only 17% (73/430) of MSAs comprised the top 2 Medicare Advantage star ratings for DMARD use. Measured detection was 0.59% (IQR = 0.47%-0.71%; CV = 0.355) on average, and 57.6% (IQR = 48%-69%; CV = 0.341) of RA patients visited a rheumatologist. MSAs with the highest DMARD use spent $26,724 (in 2015 U.S. dollars) annually treating patients with RA, $5,428 more (P < 0.001) than low DMARD-use MSAs, largely because of higher pharmacy cost ($5,090 vs. $7,610, P < 0.001). However, MSAs with higher DMARD use had lower RA-related inpatient cost ($1,890 vs. $2,342, P = 0.024). There were significant geographic variations in the quality of care received by patients with RA, although quality was poor in most areas. Fewer than 1 in 5 MSAs could be considered high quality based on patient DMARD use. Access to specialist care may be an issue, since just over half of patients with RA visited a rheumatologist annually. Efforts to incentivize better quality of care holds promise in terms of unlocking value for patients, but for some diseases, this approach may result in higher costs. The research reported in this manuscript was supported by AbbVie through consulting fees paid to Precision Health Economics (PHE). AbbVie and PHE collaborated to develop the study design and protocol. AbbVie and PHE participated in the interpretation of data, review, and approval of the manuscript. Shafrin and Shim are employed by PHE. Ganguli and Sanchez Gonzalez are employed by AbbVie. Seabury reports consulting fees from PHE. The results from this study were presented in poster form at the Academy of Managed Care Pharmacy's 2015 Annual Meeting and Expo; April 7-10, 2015; San Diego, California, and at the Academy of Managed Care Pharmacy's 2016 Annual Meeting and Expo; April 19-22, 2016; San Francisco, California. Study concept and design were contributed primarily by Shafrin, along with Ganguli and Seabury. Shafrin and Shim took the lead in data collection, and data interpretation was performed by Ganguli, Sanchez Gonzalez, Seabury, and Shafrin. The manuscript was written primarily by Shafrin, along with Shim and Seabury, and revised primarily by Ganguli, along with Sanchez Gonzalez and Seabury.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057938760

Download citation: RISBibTeXText

PMID: 27882832

DOI: 10.18553/jmcp.2016.22.12.1472


Related references

Variations and practice in the care of patients with rheumatoid arthritis: quality and cost of care. Journal of Clinical Rheumatology 20(2): 79-86, 2014

Cost effectiveness and cost utility analysis of multidisciplinary care in patients with rheumatoid arthritis: a randomised comparison of clinical nurse specialist care, inpatient team care, and day patient team care. Annals of the Rheumatic Diseases 62(4): 308-315, 2003

Quality of care of rheumatoid arthritis patients in the general population of Germany - The German rheumatoid arthritis population survey (graps). Annals of the Rheumatic Diseases 66(Suppl. 2): 341, 2007

Assessment of the Quality of Delivered Care for Iranian patients with Rheumatoid Arthritis by Using Comprehensive Quality Measurement Model in Health Care (CQMH). Journal of Caring Sciences 4(4): 287-296, 2015

The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey. Clinical and Experimental Rheumatology 30(2): 202-207, 2012

A population-based assessment of disease activity, quality of life and cost of care in early rheumatoid arthritis. Arthritis & Rheumatism 41(9 Suppl. ): S127, 1998

Practice variation in rheumatologists care of patients with rheumatoid arthritis Results from the Rheumatology Care Study. Arthritis & Rheumatism 38(9 Suppl. ): S384, 1995

Cost of illness and quality of life of patients with rheumatoid arthritis in South Korea. Value in Health 15(1 Suppl): S43-S49, 2012

Prescribing Pattern and Cost Analysis on (Dmard's) Disease Modifying Anti Rheumatoid Drugs in Rheumatoid Arthritis Patients of a Tertiary Care Teaching Hospital in South India - a Cross Sectional Study. Value in Health 17(7): A772, 2014

Cost of medical care for patients with osteoarthritis and rheumatoid arthritis A 13 year study. Arthritis & Rheumatism 39(9 Suppl. ): S71, 1996

Mo1362 Geographic Variation in Care of Patients With Inflammatory Bowel Disease Suggests Unequal Quality of Care in the United States. Gastroenterology 144(5): S-647, 2013

Geographic Variation in Quality of Care for Commercially Insured Patients. Health Services Research 52(2): 849-862, 2017

Nurse-led Care for Patients with Rheumatoid Arthritis: A Systematic Review of the Effect on Quality of Care. Journal of Rheumatology 44(6): 757-765, 2017

Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Current Medical Research and Opinion 23(8): 1749-1759, 2007

Quality of care for patients with rheumatoid arthritis. JAMA 284(8): 984-992, 2000